Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 12/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.75 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 0.75 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.75 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 0.75 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.75 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.75 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | BRD4 | O60885 | 1/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | EGFR | P00533 | 1/20 | 0.75 |
| ▸ | LTA4H | P09960 | 1/20 | 0.75 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517309 | 0.95 | HDAC4 (0.81) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL3806017 | 0.94 | MEN1 (0.73) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL6665592 | 0.93 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL137348 | 0.93 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL1065393 | 0.93 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL6669511 | 0.93 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL12659217 | 0.92 | HDAC1 (0.89) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL608911 | 0.92 | HDAC4 (0.66) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL3342586 | 0.91 | L3MBTL1 (0.80) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL12703834 | 0.90 | HDAC4 (0.69) | HDAC4HDAC1HDAC7HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116425904-A | Supported Ziegler-Natta catalyst and preparation method and application thereof | 山东京博石油化工有限公司 | 2023-07-14 | — | — | CN | claimed |
| CN-116425904-A | Supported Ziegler-Natta catalyst and preparation method and application thereof | 山东京博石油化工有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4097138-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | Avila Therapeutics, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3630784-B1 | PREPARATION OF ISOCYANATOSILANES | MOMENTIVE PERFORMANCE MAT INC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3630784-A1 | PREPARATION OF ISOCYANATOSILANES | Momentive Performance Materials Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10266554-B2 | Preparation of isocyanatosilanes | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2018222486-A1 | PREPARATION OF ISOCYANATOSILANES | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| US-20180346493-A1 | PREPARATION OF ISOCYANATOSILANES | MOMENTIVE PERFORMANCE MATERIALS INC. | 2018-12-06 | — | — | US | disclosed |
| US-6863719-B2 | Ink jet ink with improved reliability | LEXMARK INTERNATIONAL, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| EP-0962489-B1 | Crystalline polypropylene resin composition and amide compounds | NEW JAPAN CHEM CO LTD (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-6254669-B1 | Bleed reduction agents for ink printing inks | ZENECA LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| US-6235823-B1 | CRYSTALLINE POLYPROPLYLENE RESIN AND A BETA-NUCLEATING AGENT, THE BETA-NUCLEATING AGENT BEING A DIAMIDE COMPOUND. | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0557721-B1 | Polypropylene moulded articles with increased -crystal content and bisamides as -nucleating agents. | NEW JAPAN CHEM CO LTD (JP) | 2000-10-04 | — | — | EP | disclosed |
| EP-0962489-A2 | Crystalline polypropylene resin composition and amide compounds | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 1999-12-08 | — | — | EP | disclosed |
| EP-0471454-B1 | Reactive pyridone azo dyestuffs | ZENECA LTD (GB) | 1996-12-04 | — | — | EP | disclosed |
| EP-0468649-B1 | Anionic compounds | ZENECA LTD (GB) | 1996-05-15 | — | — | EP | disclosed |
| EP-0468647-B1 | Anionic compounds | ZENECA LTD (GB) | 1996-03-13 | — | — | EP | disclosed |
| EP-0468648-B1 | Anionic bis(hydroxynaphthylamino) disazo dyestuffs and use thereof for ink jet printing | ZENECA LTD (GB) | 1995-09-20 | — | — | EP | disclosed |
| US-5262527-A | Disazo dyes suitable for use in ink jet printing | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-16 | — | — | US | disclosed |
| EP-0557721-A2 | Crystalline polypropylene resin composition and amide compounds | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 1993-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346493-A1 | PREPARATION OF ISOCYANATOSILANES | IDH3A, IDH2, IDH1 | HDAC4 1337/4885HDAC1 547/4885HDAC7 867/4885 |
| US-10266554-B2 | Preparation of isocyanatosilanes | IDH3A, IDH2, IDH1 | HDAC4 1337/4885HDAC1 547/4885HDAC7 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.